Company CARsgen Therapeutics Holdings Limited

Equities

2171

KYG1996C1006

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Hong Kong S.E. Other stock markets 01:38:17 07/05/2024 pm IST			5-day change	1st Jan Change
5.88 ^HKD	+2.62%		+5.00%	-9.54%

30/04	CARsgen Therapeutics Holdings Limited Announces Abstracts from the Ongoing Studies of zevorcabtagene autoleucel and CT071 to be Presented as an Oral Presentation and a Poster Presentation, Respectively, at the Upcoming EHA 2024	CI
29/04	CARsgen Therapeutics Holdings Limited Announces Board and Committee Changes	CI

CARsgen Therapeutics Holdings Ltd is a China-based investment holding company principally engaged in discovering, developing and commercializing innovative chimeric antigen receptor (CAR)-T cell therapies. The Companyâs therapies are applied in the treatment of hematological malignancies and solid tumors. The Company have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The Company conducts its businesses in China and the United States.

Number of employees: 516

Managers	Title	Age	Since
Hua Mao Wang FOU	Founder	48	09/18/09
Zong Hai Li CEO	Chief Executive Officer	51	09/18/09
Lan Xie DFI	Director of Finance/CFO	52	01/21/01
Hong Ma CTO	Chief Tech/Sci/R&D Officer	54	01/18/01
Raffaele Baffa CTO	Chief Tech/Sci/R&D Officer	65	07/22/07
Hua Jiang BRD	Director/Board Member	45	01/21/01
Sylvie Peltier LAW	General Counsel	60	31/22/31
Guan Jun Zhou LAW	General Counsel	-	-
Wing Yat Lui SEC	Corporate Secretary	35	23/21/23
Leigh Hsu PRN	Corporate Officer/Principal	54	01/17/01

Members of the board	Title	Age	Since
Zong Hai Li CEO	Chief Executive Officer	51	09/18/09
Hua Mao Wang FOU	Founder	48	09/18/09
Xiang Ke Zhao BRD	Director/Board Member	38	04/23/04
Rong Gang Xie BRD	Director/Board Member	39	18/20/18
Bing Sen Guo BRD	Director/Board Member	54	13/18/13
Hua Qing Guo BRD	Director/Board Member	36	18/20/18
Guang Mei Yan BRD	Director/Board Member	67	18/21/18
Hua Jiang BRD	Director/Board Member	45	01/21/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	575,643,915	337,956,699 ( 58.71 %)	0	58.71 %

Name	Equities	%	Valuation
Zong Hai Li 37.45 %	215,572,730	37.45 %	166 M $
Aegon-Industrial Fund Management Co., Ltd. 3.992 %	22,981,000	3.992 %	18 M $
Loyal Valley Capital Co. Ltd. 3.860 %	22,222,244	3.860 %	17 M $
Shanghai Bioveda Investment Management Consulting Co. Ltd. 1.098 %	6,317,706	1.098 %	5 M $
Fullgoal Fund Management Co., Ltd. 1.058 %	6,087,500	1.058 %	5 M $
China Asset Management Co., Ltd. 0.6320 %	3,638,000	0.6320 %	3 M $
GF Fund Management Co., Ltd. 0.6235 %	3,589,000	0.6235 %	3 M $
Hua Jiang 0.5005 %	2,880,992	0.5005 %	2 M $
Bosera Asset Management Co., Ltd. 0.4637 %	2,669,500	0.4637 %	2 M $
Bank of China Investment Management Co., Ltd. 0.4508 %	2,595,000	0.4508 %	2 M $

CARsgen Therapeutics Holdings Ltd.

CMC Preparation Center No. 388 Yindu Road

200231, Shanghai

http://www.carsgen.com

address CARsgen Therapeutics Holdings Limited(2171)

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

5.425 CNY

Average target price

6.662 CNY

Spread / Average Target

+22.79%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
CARSGEN THERAPEUTICS HOLDINGS LIMITED	-9.54%	422M
REGENERON PHARMACEUTICALS, INC.	+10.44%	106B
VERTEX PHARMACEUTICALS INCORPORATED	+0.82%	104B
ARGENX SE	+6.72%	23.25B
BIONTECH SE	-13.89%	22.5B
GENMAB A/S	-6.64%	18.7B
WUXI APPTEC CO., LTD.	-37.26%	17.95B
BEIGENE, LTD.	-10.98%	16.99B
NEUROCRINE BIOSCIENCES, INC.	+8.67%	14.26B
SAREPTA THERAPEUTICS, INC.	+41.08%	12.76B

Bio Therapeutic Drugs